# BPC-157 Frequently Asked Questions

> Answers to the most common questions about BPC-157: what it is, what the research shows, FDA and compounding status, WADA prohibition, pharmacokinetics, and human clinical data.

Answers drawn from the published peer-reviewed literature. This is not medical advice.

## What is BPC-157 and where does it come from?

BPC-157 stands for Body Protection Compound 157. It is a synthetic 15-amino-acid peptide with the sequence GEPPPGKPADDAGLV and a molecular weight of 1,419.54 Da. The 'body protection compound' designation came from its origin in studies of human gastric juice — specifically from a protein found in that juice — but the peptide used in research today is produced by solid-phase peptide synthesis (SPPS), not extracted from biological material [16, 20]. The compound also appears in the literature under the designations PL 14736 and PLD-116. Research-grade material is supplied as a lyophilized acetate salt, specified at ≥98% purity by HPLC.

## What does the research say about BPC-157 for tissue repair?

The preclinical record is extensive and consistent across multiple tissue types. In rat models, BPC-157 at 10 μg/kg intraperitoneal improved tendon-to-bone healing after Achilles detachment [1], accelerated transected Achilles tendon healing [2], improved medial collateral ligament healing across three routes of administration [4], and restored myotendinous junction integrity with full functional recovery by day 28–42 [6]. The consistent molecular mechanism is VEGFR2 upregulation driving angiogenesis via the Akt-eNOS nitric oxide pathway [16]. A 2025 systematic review from Vasireddi and colleagues confirmed enhanced fibroblast proliferation, collagen synthesis, myogenesis, and osteogenesis across rodent models [17]. All of this is preclinical — no controlled human trials have been conducted.

## What is the current FDA status of BPC-157?

As of mid-2026: BPC-157 has no FDA approval for any human indication and no IND (Investigational New Drug) application filed in the United States. The compound was placed on the FDA's 503A Category 2 list in September 2023, which prohibited compounding pharmacies operating under Section 503A of the FDCA from producing it. In April 2026, the FDA removed BPC-157 (and TB-500) from Category 2 following withdrawal of their nominations — but did not place either compound on the 503A Bulks List (the permitted list). The FDA's Pharmacy Compounding Advisory Committee (PCAC) is scheduled to formally review BPC-157 free base and BPC-157 acetate in July 2026, with ulcerative colitis as the nominated use case. The outcome of that review is not yet known.

## What is the current compounding pharmacy status of BPC-157?

As of mid-2026, BPC-157 is in a regulatory gray zone for compounding pharmacies: it is no longer on the 503A Category 2 list (which prohibits compounding), but it is also not on the 503A Bulks List (which authorizes it). The April 2026 Category 2 removal created legal ambiguity about whether 503A compounding pharmacies can legally compound BPC-157. The July 2026 PCAC review is the mechanism by which the FDA will evaluate whether to add it to the Bulks List. Until that review produces a recommendation and the FDA acts on it, compounding status remains unresolved. This site tracks the regulatory record but does not provide legal or compliance advice.

## What are the pharmacokinetics of BPC-157 — half-life and bioavailability?

BPC-157 has a very short plasma elimination half-life in preclinical pharmacokinetic studies. In rats given BPC-157 intravenously, t1/2 was 15.2 minutes. In beagle dogs given BPC-157 intravenously, t1/2 was 5.27 minutes — the shortest half-life in the published record. The compound was undetectable in plasma at four hours post-administration in both species. Intramuscular bioavailability was 14–19% in rats and 45–51% in dogs relative to IV [20]. Oral bioavailability is not formally characterized but the compound is active by oral route in rodent models, likely due to its unusual stability in gastric juice (>24 hours) and local GI receptor activation. No human pharmacokinetic data have been published.

## What human clinical data exists for BPC-157?

Three small published human studies exist as of 2025. First, a 16-patient knee pain pilot study reported significant pain relief in 14 of 16 patients via intra-articular injection. Second, a 2024 pilot study in 12 patients with moderate-to-severe interstitial cystitis refractory to pentosan polysulfate showed 80–100% symptom resolution at six weeks via intravesicular BPC-157 injections [18]. Third, a two-subject IV safety study documented tolerance up to 20 mg IV without adverse events [16]. None of these are randomized controlled trials. A Phase 2 IBD trial (PL 14736, oral) conducted by Pliva produced results that were never published in peer-reviewed literature — a significant gap the clinical literature frequently cites.

## Is BPC-157 banned in professional sports?

Yes. WADA (the World Anti-Doping Agency) has listed BPC-157 under Section S0 — Non-Approved Substances — since 2022. Section S0 prohibits any substance that has no current approval by any governmental regulatory health authority for human therapeutic use, regardless of route of administration or dose. Athletes in WADA-governed competition who use BPC-157 are in violation of the WADA Code. This prohibition applies globally across all sports governed by WADA and national anti-doping organizations that follow the WADA Code.

## What purity standards apply to research-grade BPC-157?

Research-grade BPC-157 is typically specified at ≥98% purity by reverse-phase HPLC (RP-HPLC) with ESI-MS confirmation of molecular weight and identity. Some commercial sources specify >95% (the 2025 Demirtas ischemia-reperfusion study used Sigma-Aldrich material at >95% purity [14]). The salt form matters: BPC-157 acetate and BPC-157 free base have different molecular weights and handling properties, and the FDA's July 2026 PCAC review evaluates them separately. Anti-doping detection has been validated to 0.01–0.11 ng/mL in urine by UHPLC-HRMS, characterizing nine metabolites produced primarily by amide-bond degradation [19].

## What are the most recent BPC-157 studies from 2024 and 2025?

Four studies from 2024–2025 are particularly notable. The 2025 McGuire narrative review (Current Reviews in Musculoskeletal Medicine) synthesized all three human studies and all preclinical evidence, concluding BPC-157 should be considered investigational [16]. The 2025 Vasireddi systematic review (HSS Journal) confirmed consistent pro-healing findings across musculoskeletal models and called for human RCTs [17]. The 2025 Demirtas study (Medicina) showed BPC-157 at 20 μg/kg IP protected liver, kidney, and lung from ischemia-reperfusion distant organ damage [14]. The 2024 Lee pilot study (Alternative Therapies in Health and Medicine) reported 80–100% IC symptom resolution in 12 patients via intravesicular injection [18].

## What tissues and organ systems has BPC-157 been studied in?

The preclinical literature covers a wide range: tendon (Achilles, medial collateral ligament), muscle (myotendinous junction, skeletal muscle), bone (segmental defects in rabbits), gastric mucosa (ulcer models), intestinal/colonic mucosa (ischemia and ischemia-reperfusion models), liver (alcohol-induced portal hypertension, ischemia-reperfusion), kidney (ischemia-reperfusion distant organ damage), lung (ischemia-reperfusion distant organ damage), spinal cord (compression injury models), brain (antidepressant-like behavioral effects), and cardiac tissue (isoprenaline-induced myocardial infarction). The breadth across organ systems reflects the compound's VEGFR2/Akt-eNOS mechanism, which operates wherever vascular endothelium and nitric oxide signaling are relevant — which is essentially everywhere.

## What is the difference between BPC-157 free base and BPC-157 acetate?

BPC-157 is synthesized as a peptide and then counterbalanced with an acid to form a stable salt. The acetate salt (BPC-157 acetate) is the most common research form — acetic acid is used as the counterion and the resulting salt is more stable for lyophilization and reconstitution than the free base form. BPC-157 free base refers to the peptide without any counterion. The two forms differ slightly in molecular weight (the acetate counterion adds mass) and may differ in reconstitution behavior. The FDA's July 2026 PCAC review addresses both forms separately for 503A compounding pharmacy inclusion, reflecting regulatory recognition that they are distinct chemical entities.

## Does BPC-157 cause cancer — what does the research say about oncology risk?

The theoretical concern about BPC-157 and oncology risk stems from the compound's angiogenic properties. Pathological angiogenesis can promote tumor vascularization — it is one mechanism by which tumors secure blood supply. If BPC-157 drives angiogenesis indiscriminately, there is a theoretical concern about promoting tumor growth. The published preclinical data on this question actually showed anti-tumor properties in animal models, not pro-tumor effects. However, the research community has not definitively closed this question, and it is listed among the legitimate open research questions in regulatory and review literature [16, 17]. This is an area where the preclinical data do not yet provide a complete answer, and where human data are absent.

## What routes of administration has BPC-157 been studied with?

Eight routes appear across the preclinical and clinical literature: intraperitoneal (IP, dominant in rat models), oral gavage and drinking water concentrate, intramuscular (IM), intravenous (IV, formal PK studies and one human safety study), topical cream, bath application (direct application to a tissue surface in surgical models), intra-articular (one human knee pain pilot), and intravesicular (one human IC pilot). Route equivalence was explicitly demonstrated in the MCL healing study, where IP, oral drinking water, and topical cream produced equivalent functional, biomechanical, and histological outcomes over 90 days [4]. Intraperitoneal is not a clinically translatable route for most human applications.

## Does BPC-157 have an antidepressant effect?

In preclinical models, yes — with the usual caveats about rodent behavioral studies. BPC-157 at 10 μg/kg and 10 ng/kg intraperitoneal in rats produced a significant anti-immobility effect in Porsolt's forced swim test, comparable to imipramine 15 mg and nialamide 40 mg. Notably, BPC-157 maintained its effect under chronic unpredictable stress conditions, where the reference antidepressants lost efficacy [9]. The mechanism for CNS effects is less characterized than the vascular pathway — it may involve NO synthesis in neural tissue or neurovascular effects — and no human studies have examined BPC-157 for mood-related outcomes.

---

An independent editorial digest of the peer-reviewed BPC-157 research record.